ArticleFrontiers in endocrinology2025
Clomiphene citrate reduces premature LH surge in obese women during controlled ovarian stimulation: a retrospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modified clomiphene citrate protocol versus gonadotropin-releasing hormone antagonist protocol inFrontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clomiphene citrate effectively suppressed the negative feedback of estrogen on the hypothalamus and induces premature luteinizing hormone (LH) surge during controlled ovulation stimulation, while obese women often have impaired hypothalamic-pituitary function. This study aimed to investigate whether the utilization of clomiphene citrate for controlled ovulation stimulation in obese women can effectively decrease the likelihood of premature LH surge. Methods: A retrospective study was conducted on women under the age of 38 with normal menstrual cycles and ovarian reserve who underwent controlled ovulation stimulation (COH) using clomiphene citrate. The participants were categorized by the Asian body mass index (BMI) classification. The dynamic reproductive endocrinological profiles during COH, especially the probability of serum LH concentration exceeding 10 IU/L, as well as the outcomes related to the embryo development and pregnancy, were compared among three BMI groups. Results: The basal levels of LH exhibited a significant reduction in overweight and obese women (p<0.001). Additionally, there was a significant decrease in the incidence of LH concentration exceeding 10 IU/L during controlled ovulation stimulation among overweight and obese women (7.19% vs 3.62% vs2.27%, p<0.05). Moreover, there were no significant differences observed among the three BMI groups regarding embryo transfer numbers, implantation, pregnancy or live birth rates. Conclusions: In obese women, clomiphene citrate effectively controlled LH levels, resulting a low prevalence of premature LH surge compared to patients with normal weight. This evidence contributes to a safer and more effective treatment for infertility in obese individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.